Guobang Pharma Ltd banner
G

Guobang Pharma Ltd
SSE:605507

Watchlist Manager
Guobang Pharma Ltd
SSE:605507
Watchlist
Price: 23.92 CNY -1.24% Market Closed
Market Cap: ¥13.4B

Guobang Pharma Ltd
Net Issuance of Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Guobang Pharma Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
G
Guobang Pharma Ltd
SSE:605507
Net Issuance of Debt
¥218.2m
CAGR 3-Years
-24%
CAGR 5-Years
22%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Issuance of Debt
-¥22.4m
CAGR 3-Years
19%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Issuance of Debt
-¥4.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Issuance of Debt
¥26.9m
CAGR 3-Years
-32%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhejiang Nhu Co Ltd
SZSE:002001
Net Issuance of Debt
-¥916.4m
CAGR 3-Years
N/A
CAGR 5-Years
-71%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Issuance of Debt
¥1.5B
CAGR 3-Years
93%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Guobang Pharma Ltd
Glance View

Market Cap
13.4B CNY
Industry
Pharmaceuticals

Guobang Pharma Ltd. has carved its niche within the pharmaceutical industry as an integrated player blending advanced chemical synthesis with pharmaceutical manufacturing. At its core, the company thrives on the development and production of active pharmaceutical ingredients (APIs), which are crucial components for a multitude of medications. Leveraging a robust research and development framework, Guobang Pharma consistently delivers high-quality APIs to both domestic and international clients, ensuring a steady flow of income. This strategic approach, combining a focus on innovative technology and stringent quality control, positions the company as a reliable partner in the global pharmaceutical supply chain. In addition to API production, Guobang Pharma extends its business model through the formulation and manufacturing of finished pharmaceutical products. By operating across this entire value chain, Guobang can capture a larger slice of the industry's revenue pie. The company’s diversified portfolio not only includes essential medicines but also specialty and generic drugs, allowing it to navigate market shifts and regulatory landscapes adeptly. This vertical integration enhances its competitive advantage by reducing dependency on external suppliers while contributing to its bottom line growth, as it fulfills varied market demands from development to distribution.

Intrinsic Value
23.75 CNY
Overvaluation 1%
Intrinsic Value
Price ¥23.92
G

See Also

What is Guobang Pharma Ltd's Net Issuance of Debt?
Net Issuance of Debt
218.2m CNY

Based on the financial report for Dec 31, 2025, Guobang Pharma Ltd's Net Issuance of Debt amounts to 218.2m CNY.

What is Guobang Pharma Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
22%

The average annual Net Issuance of Debt growth rates for Guobang Pharma Ltd have been -24% over the past three years , 22% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett